Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF1031 - Provider product page
- Provider
- R&D Systems
- Product name
- Human ADAM8 Ectodomain Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human ADAM8 Ectodomain in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse ADAM8 is observed and less than 1% cross-reactivity with recombinant human (rh) ADAM12, rhADAM19, and rhADAM33 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
P78325- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression.
ADAM8 as a drug target in pancreatic cancer.
Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.
Theodorou K, van der Vorst EPC, Gijbels MJ, Wolfs IMJ, Jeurissen M, Theelen TL, Sluimer JC, Wijnands E, Cleutjens JP, Li Y, Jansen Y, Weber C, Ludwig A, Bentzon JF, Bartsch JW, Biessen EAL, Donners MMPC
Scientific reports 2017 Sep 15;7(1):11670
Scientific reports 2017 Sep 15;7(1):11670
ADAM8 as a drug target in pancreatic cancer.
Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, Moss ML, Rasmussen FH, Miller MA, Lauffenburger DA, Tuveson DA, Nimsky C, Bartsch JW
Nature communications 2015 Jan 28;6:6175
Nature communications 2015 Jan 28;6:6175
Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.
Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grénman R, James HA, Edwards DR, Kähäri VM
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 1;16(7):2022-35
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 1;16(7):2022-35
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- ADAM8 in Human PBMCs. ADAM8 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human ADAM8 Ectodomain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1031) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasmic. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
